A Study Exploring Two Treatment Strategies in Patients With Atrial Fibrillation Who Undergo Catheter Ablation Therapy
Phase 3
Completed
- Conditions
- Atrial Fibrillation
- Interventions
- Drug: uninterrupted vitamin K antagonist (VKA)
- First Posted Date
- 2012-11-20
- Last Posted Date
- 2017-03-06
- Lead Sponsor
- Janssen Scientific Affairs, LLC
- Target Recruit Count
- 253
- Registration Number
- NCT01729871
Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT-AF II)
Completed
- Conditions
- Atrial Fibrillation
- First Posted Date
- 2012-10-05
- Last Posted Date
- 2025-02-03
- Lead Sponsor
- Janssen Scientific Affairs, LLC
- Target Recruit Count
- 13769
- Registration Number
- NCT01701817
An Open-label Evaluation of Tapentadol Extended Release (ER) in Participants With Moderate to Severe Chronic Pain After Conversion From Hydrocodone, Oxycodone Controlled Release (CR), and/or Morphine Sustained Release (SR)
Phase 4
Withdrawn
- Conditions
- Chronic Back PainPainChronic Low Back PainOsteoarthritis Pain In The Hip or Knee
- Interventions
- First Posted Date
- 2012-06-29
- Last Posted Date
- 2018-01-25
- Lead Sponsor
- Janssen Scientific Affairs, LLC
- Registration Number
- NCT01631513
Velcade (Bortezomib) Consolidation After Transplant
Phase 3
Completed
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2012-02-27
- Last Posted Date
- 2025-02-04
- Lead Sponsor
- Janssen Scientific Affairs, LLC
- Target Recruit Count
- 256
- Registration Number
- NCT01539083
Pharmacokinetics Study of Oral Rivaroxaban in Healthy Participants
Phase 1
Completed
- Conditions
- Healthy ParticipantsPharmacokineticsBioavailability
- Interventions
- First Posted Date
- 2011-11-03
- Last Posted Date
- 2017-01-24
- Lead Sponsor
- Janssen Scientific Affairs, LLC
- Target Recruit Count
- 55
- Registration Number
- NCT01464450
A Study to Evaluate the Efficacy of Paliperidone Palmitate in the Prevention of Relapse of the Symptoms of Schizoaffective Disorder
Phase 3
Completed
- Conditions
- Schizoaffective Disorder
- Interventions
- Drug: Placebo
- First Posted Date
- 2010-09-01
- Last Posted Date
- 2015-01-05
- Lead Sponsor
- Janssen Scientific Affairs, LLC
- Target Recruit Count
- 667
- Registration Number
- NCT01193153
Research and Evaluation of Antipsychotic Treatment in Community Behavioral Health Organizations
Completed
- Conditions
- SchizophreniaBipolar Disorder
- Interventions
- First Posted Date
- 2010-08-13
- Last Posted Date
- 2014-02-12
- Lead Sponsor
- Janssen Scientific Affairs, LLC
- Target Recruit Count
- 1066
- Registration Number
- NCT01181960
- Locations
- 🇺🇸
Neuropsychiatry Clinic and Research Center, Bullhead City, Arizona, United States
🇺🇸Shanti Clinical Trials, Colton, California, United States
🇺🇸Sun Valley Research Center, Imperial, California, United States
Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF)
Completed
- Conditions
- Atrial Fibrillation
- First Posted Date
- 2010-07-20
- Last Posted Date
- 2017-01-24
- Lead Sponsor
- Janssen Scientific Affairs, LLC
- Target Recruit Count
- 10179
- Registration Number
- NCT01165710
15 Month Study for Adults Who Have Been Diagnosed With Schizophrenia and Incarcerated
Phase 4
Completed
- Conditions
- Schizophrenia
- Interventions
- First Posted Date
- 2010-07-07
- Last Posted Date
- 2015-04-24
- Lead Sponsor
- Janssen Scientific Affairs, LLC
- Target Recruit Count
- 450
- Registration Number
- NCT01157351
A Single-arm, Open-label, Study to Assess the Pharmacokinetics of Darunavir and Ritonavir, Darunavir and Cobicistat, Etravirine, and Rilpivirine in HIV-1 Infected Pregnant Women
Phase 3
Completed
- Conditions
- HIVPregnancyHIV Infections
- Interventions
- First Posted Date
- 2009-03-04
- Last Posted Date
- 2018-07-06
- Lead Sponsor
- Janssen Scientific Affairs, LLC
- Target Recruit Count
- 77
- Registration Number
- NCT00855335